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Abstract
Background: Interleukin-17 (IL-17)-producing cells are increasingly considered to be the major
pathogenic population in various autoimmune disorders. The effects of glucocorticoids, widely used
as therapeutics for inflammatory and autoimmune disorders, on IL-17 generation have not been
thoroughly investigated so far. Therefore, we have explored the influence of methylprednisolone
(MP) on IL-17 expression in rat lymphocytes, and compared it to the effect of the drug on
interferon (IFN)-γ.
Results: Production of IL-17 in mitogen-stimulated lymph node cells (LNC) from non-treated rats,
as well as in myelin basic protein (MBP)-stimulated draining LNC from rats immunized with spinal
cord homogenate and complete Freund's adjuvant was significantly reduced by MP. The reduction
was dose-dependent, sustained through the follow-up period of 48 hours, and was not achieved
through anti-proliferative effect. Additionally, MP inhibited IL-17 production in purified T cells as
well, but to less extent than in LNC. In its influence on IL-17 production MP inhibited Ror-γT
transcription factor expression, as well as Jun phosphorylation, but not ERK or p38 activation in
mitogen-stimulated LNC. Importantly, MP collaborated with IFN-γ in inhibiting IL-17 generation in
LNC.
Conclusion: The observed difference in the effect of MP on IL-17 and IFN-γ could be important
for the understanding of the variability in the efficiency of glucocorticoids in the treatment of
autoimmune diseases.
Background
Interleukin-17 (IL-17A or IL-17) is the prototypic member
of a newly identified cytokine family which comprises five
other relatives: IL-17B-F [1]. This cytokine exerts its pleio-
tropic effects by binding to the IL-17 receptor with ubiq-
uitous tissue and cell distribution. It promotes
inflammation through enhancing the production of
diverse pro-inflammatory cytokines and mediators,
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including IL-6, IL-8, G-CSF, leukemia inhibitory factor,
PGE2, nitric oxide, as well as proliferation, maturation
and chemotaxis of neutrophiles [2]. It is mainly produced
by effector and memory CD4+ T lymphocytes developed
from a unique lineage of CD4+ T cells distinct from Th1
and Th2 effectors, and negatively regulated by their
respective signature cytokines IFN-γ and IL-4 [3,4]. These
newly described effectors – Th17 cells, at least in mice,
develop from naïve CD4+ T cells under the influence of
TGF-β and IL-6 [5-7], require IL-23 for survival and expan-
sion [8], and secrete a profile of inflammatory cytokines
including IL-17 and IL-17F, IL-6, GM-CSF, TNF-α, IL-21
and IL-22 [2]. IL-17 has emerged as a crucial pathogenic
factor in several autoimmune and inflammatory diseases
induced in experimental animals, such as experimental
autoimmune encephalomyelitis (EAE), collagen induced
arthritis (CIA), inflammatory bowel disease (IBD), previ-
ously thought to be mediated by Th1 cells [9]. Addition-
ally, dysregulation of IL-17 production was found to be
associated with many chronic inflammatory diseases in
humans, such as rheumatoid arthritis (RA), asthma, IBD,
multiple sclerosis (MS), psoriasis vulgaris, as well as with
allograft rejection [10].
Glucocorticoids (GCs) are steroid hormones that are
among the most potent immunosuppressive and anti-
inflammatory drugs currently available. Synthetic GCs are
efficacious in the treatment of numerous inflammatory
and autoimmune diseases and in preventing graft rejec-
tion, while endogenously produced GCs play an essential
and complex role in the regulation of the immune
response [11]. They have been shown to affect both innate
and adaptive immune response by influencing cell traf-
ficking, proliferation, expression of surface molecules,
such as MHC, co-stimulatory and adhesion molecules,
and synthesis of many inflammatory mediators, including
cytokines [11]. GCs exert most, if not all, of their effects
through binding to the glucocorticoid receptor (GR), a lig-
and-activated transcription factor [12,13]. Their influence
on T cell functions is both direct and indirect, via antigen-
presenting cells (APCs). It is known that GC-GR com-
plexes inhibit both T cells and APCs functions by affecting
key transcription factors involved in the regulation of
expression of a number of inflammatory cytokines, such
as IFN-γ, TNF-α and IL-2 [14]. Additionally, several stud-
ies clearly showed both in animals and humans that the
presence of GCs enhanced Th-2 cytokines IL-4, IL-10 and
IL-13 at the same time as they decreased Th-1 cytokines
secretion by CD4+ lymphocytes [15,16].
Since compelling evidence indicate that GCs differentially
regulate the production of Th1 and Th2 cytokines, it is
important to know whether and if so, how GCs affect the
production of IL-17, a cytokine accused to be critically
involved in the pathogenesis of autoimmune and chronic
inflammatory diseases frequently treated with GCs. There-
fore, the aim of this study was to analyze in vitro effects of
methylprednisolone (MP), a synthetic glucocorticoid
drug, on mitogen- and antigen-induced expression and
production of IL-17 in the rat and to compare these effects
to corresponding effects on IFN-γ. As the result, we show
that MP inhibits mitogen- and antigen-induced IL-17
expression, but less potently than corresponding IFN-γ
expression.
Methods
Experimental animals
Inbred Dark Agouti (DA) and Albino Oxford (AO) rats
were obtained from animal breeding facility of the Insti-
tute for Biological Research "Siniša Stanković" (Belgrade)
and were kept under standardized conditions. Age- and
gender-matched animals, 12–16 weeks old, were used for
experiments. Rats were housed under conventional condi-
tions with laboratory chow and water ad lib. For the exper-
iments investigating antigen-specific production of
cytokines, DA rats were immunized with mixture of rat
spinal cord homogenate and complete Freund's adjuvant
(SCH-CFA), as described previously [17]. All experiments
were approved by the Ethical Committee of the Institute
for Biological Research "Siniša Stanković" (IBISS, N° 16/
07).
Chemicals, cells and cell cultures
Methylprednisolone (MP) was from Hemofarm (Vršac,
Serbia), concanavalin A (ConA) was from Pharmacia
(Uppsala, Sweden), guinea pig myelin basic protein
(MBP) was a kind gift of Dr Alexander Fluegel (Max-
Planck Institute for Neurobiology, Martinsried, Ger-
many). ERK-inhibitor UO126, p38-inhibitor SB202190
and Jnk-inhibitor SP600125 were from Sigma (Deisen-
hofen, Germany). Neutralizing anti-IFN-γ antibody and
isotype control antibody of irrelevant specificity were
from Holland Biotechnology (Leiden, The Netherlands).
Cervical, popliteal, inguinal and para-aortal lymph node
cells (LNC) were isolated from healthy animals, and
draining popliteal lymph node cells (DLNC) and cells
infiltrating spinal cord (SCC) from DA rats immunized
with SCH-CFA, as described previously [17]. All the cells
were grown at 5% CO2 and 37°C in RPMI-1640 (Sigma)
supplemented with antibiotics and 5% fetal calf serum
(PAA Laboratories, Pasching, Austria) for LNC or 2% rat
serum for DLNC and SCC. LNC were stimulated with
ConA (2.5 μg/ml) and were seeded in 96-well plates for
proliferation assay (2 × 105 cells/200 μl) or in 24-well
plates (2 × 106/ml) for determination of cytokines. DLNC
and SCC were seeded in 96-well plates (5 × 105/200μl)
and stimulated with MBP (10 μg/ml). For the purification
of T cells, anti- rat CD3-biotin conjugated antibody (BD
Biosciences, San Diego, CA) and MACS streptavidin
microbeads and MACS separation columns were usedBMC Immunology 2008, 9:47 http://www.biomedcentral.com/1471-2172/9/47
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according to the instructions of the manufacturer
(Miltenyi Biotec, Aubum, CA). The obtained cells were
more than 98% positive for CD4 or CD8 as deduced by
cytofluorometry (FACS Calibur, BD Biosciences), and
were stimulated with plate bound anti-CD3 (1 μg/ml)
and anti CD28 (1 μg/ml) antibodies (eBioscience, San
Diego, CA). The population of CD3- cells, obtained by the
same procedure as cells that were not bound to CD3-
biotin conjugated antibody which were more than 98%
negative for CD3 (as deduced by cytofluorimetry), were
stimulated with LPS (1 μg/ml, Sigma).
Reverse transcription- real time polymerase chain reaction
In order to determine cytokine? gene expression real time
PCR was performed. First, total RNA was isolated from the
cells and 1 μg of the isolated RNA was reverse transcribed
using random hexamer primers and MMLV (Moloney
Murine Leukemia Virus) reverse transcriptase, according
to manufacturer's instruction (Fermentas, Vilnius, Lithua-
nia). The prepared cDNAs were amplified using TaqMan
Universal PCR Master Mix (Perkin Elmer/Applied Biosys-
tems Foster City, CA) according to the recommendations
of the manufacturer in a total volume of 20 μl in an ABI
PRISM 7500 Sequence Detection System (Applied Biosys-
tems). Thermocycler conditions comprised an initial step
at 95°C for 10 minute, which was followed by a 2-step
PCR program at 95°C for 15 seconds and 60°C for 60 sec-
onds for 40 cycles. Data were collected and quantitatively
analyzed using SDS 2.1 software (Applied Biosystems).
Rat β-actin gene was used as an endogenous control for
sample normalization. Results were presented relative to
the expression of β-actin. The PCR primers and probes
detecting IFN-γ, IL-17, RorγT and β-actin were as follows:
IFN-γ forward primer 5'-TGG CAT AGA TGT GGA AGA
AAA GAG-3'; IFN-γ- reverse primer 5'-TGC AGG ATT TTC
ATG TCA CCA T-3'; IFN-γ probe FAM 5'-TTT TGC CAG
TTC CTC CAG ATA TCC AAG AAG A-3' TAMRA; IL-17 for-
ward primer 5'-ATC AGG ACG CGC AAA CAT G-3'; IL-17
reverse primer 5'-TGA TCG CTG CTG CCT TCA C-3'; IL-17
probe FAM 5'-CTT CAT CTG TGT CTC TGA TGC TGT TGC
TGC-3' TAMRA; RorγT forward primer 5'-GAC AGGG
CCCC ACA GAG A-3'; RorγT reverse primer 5'-TTT GTG
AGG TGT GGG TCT TCT TT-3'; RorγT probe: FAM 5'-CGA
ACA TCT CGG GAG TTG CTG GCT-3' TAMRA; β-actin for-
ward primer 5'-GCT TCT TTG CAG CTC CTT CGT-3'; β-
actin reverse primer 5'-CCA GCG CAG CGA TAT CG-3'; β-
actin probe VIC 5'-CAC CCG CCA CCA GTT CGC CAT-3'
TAMRA. Accumulation of PCR products was detected in
real time by monitoring the probe cleavage-induced
mobilization of the reporter dye.
ELISA and cell-based ELISA
Cells were cultivated for 3 h – 72 h as indicated in the
Results section. Subsequently, cell culture supernatants
were collected and cells pelleted by centrifugation (500 g,
3 min). Cell-free supernatants were frozen until analyzed
by the protocol recommended by the manufacturers of
the ELISA kits (OptEIA Mouse IL-17 Set, BD Biosciences;
rat IFN-γ and rat IL-6 ELISA DuoSets, R&D systems, Min-
neapolis, MN). Cell-based ELISA (cELISA) was performed
as described previously [18]. In brief, 4 × 105 cells were
attached to plastic surface of 96-weel plates by poly-l-
lysine coating. They were grown over-night in RPMI sup-
plemented with 0.5% fetal calf serum, treated with MP for
2 hours and subsequently stimulated with ConA for 40
minutes. Finally, cells were fixed with paraformaldehyde
and exposed to antibodies specific for p-ERK, p-p38, p-
JNK, p-Jun and c-Fos, and corresponding secondary anti-
bodies conjugated to horse-radish peroxidase (Santa Cruz
Biotechnology, CA). Obtained values of absorbance were
normalized to relative cell number, detected by crystal-
violet staining.
Cell proliferation assay
Cell proliferation was measured by incorporation of 3H-
thymidine (Sigma) into DNA and by staining with car-
boxy-fluorescein diacetate succinimidyl ester (CFSE,
Sigma). 3H-thymidine (5 μCi/ml) was added to cell cul-
tures during last 16 h of 72 h incubation period of LNC.
Its incorporation into cellular DNA, expressed as counts
per minute (cpm), was determined in a scintillation coun-
ter. For CFSE staining LNC were exposed to 5 μM CFSE for
10 minutes, intensively washed and then cultivated for
additional 48 hours. Subsequently, cells were subjected to
flow cytofluorimetry and results analyzed with Cell Quest
software (BD Biosciences).
Statistical analysis
The results are presented as mean+/-SD of values obtained
in a representative from at least three separate experi-
ments with similar data. For EAE experiments, at least 15
rats per experiment were used, and the presented data
were obtained from 3 or 4 rats per time point. Student's t
test was performed for statistical analysis. A p value less
than 0.05 was considered statistically significant.
Results
Methylprednisolone inhibits IL-17 and IFN-γ expression in 
mitogen-stimulated lymph node cells
Lymph node cells (LNC) isolated from DA rats were stim-
ulated with concanavalin A (ConA, 2.5 μg/ml) for 48
hours in the presence or absence of various methylpred-
nisolone (MP) concentrations (0.1 – 100 ng/ml). As a
result, clear dose-dependent inhibition of IL-17 produc-
tion was observed (Fig 1A). Similar results were obtained
if LNC from AO rats were used (Fig 1B), thus excluding
strain-specificity of the observed effect. In order to rule out
that the observed effect of MP on cytokine production was
a consequence of the restriction of cell proliferation or via-
bility,  3H-thymidine incorporation assay, CFSE stainingBMC Immunology 2008, 9:47 http://www.biomedcentral.com/1471-2172/9/47
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and trypan-blue exclusion test were performed. Although
MP inhibited LNC proliferation in the highest dose (100
ng/ml), it did not significantly affect cell proliferation (Fig
1A, H), nor cell viability (data not shown) in doses equal
or below 10 ng/ml. Consequently, MP of 10 ng/ml was
used in the following experiments. The effect of MP was
sustained throughout 48 hours of follow-up period, dur-
ing which check-points were at 3 h, 6 h, 24 h, 48 h (Fig
1C). In an attempt to elucidate if MP inhibits the
cytokines production through restriction of the gene
expression, RT-PCR was conducted. Marked inhibitory
effect of MP on the cytokines' gene expression induced by
ConA stimulation was observed after 6 and 24 hours of
incubation (Fig 1E, F). Thus, these results strongly sug-
gested that MP potently inhibits both IL-17 and IFN-γ pro-
duction through inhibition of mRNA generation.
Importantly, MP also inhibited gene expression of the
essential IL-17-promoting transcription factor RorγT (Fig
1G), thus suggesting that the observed inhibition of IL-17
production was, at least partly, mediated through down-
regulation of RorγT expression.
Methylprednisolone inhibits antigen-specific production of 
IL-17 and IFN-γ
As glucocorticoids are widely used in the treatment of
CNS autoimmunity, we investigated the influence of MP
on myelin basic protein (MBP)-induced IL-17 produc-
tion. Cells for the investigation were isolated from drain-
ing lymph nodes (DLNC) of DA rats in the inductive
phase of EAE (day 6 p.i.) or spinal cords (SCC) at the
onset of the disease (day 10 p.i.). After isolation, both
DLNC and SCC were cultivated for 72 hours with MBP
(10 μg/ml) in the presence or absence of MP (10 ng/ml).
As presented in Fig 2, release of IL-17 and IFN-γ from
DLNC and SCC were markedly down-regulated in the
presence of MP. Similar results were obtained if MP was
applied to cultures that were not stimulated with MBP
(spontaneous ex vivo release, data not shown), thus fur-
ther fortifying the observation about the potency of MP in
down-regulation of IL-17 and IFN-γ in lymphocytes from
immunized rats. Together, these results clearly showed
that MP inhibits antigen-induced production of IL-17, but
once again, its effect on IFN-γ was more pronounced than
on IL-17.
Methylprednisolone inhibits IL-17 and IFN-γ production in 
T lymphocytes
In order to investigate whether the observed inhibition of
IL-17 production in LNC was a consequence of direct or
indirect effect of MP on T cells, CD3+ cells separation from
LNC was performed. These cells were stimulated with
anti-CD3 and anti-CD28 antibodies (both at 1 μg/ml) in
the absence or presence of MP (10 ng/ml) for 24 and 48
hours, and cell culture supernatants were analyzed for the
concentration of IL-17 and IFN-γ. As the result, MP inhib-
ited IL-17 generation in purified T lymphocytes, but less
efficiently than in LNC (Fig 3A, B), thus suggesting that
The effect of MP on IL-17 and IFN-γ gene expression and  production in LNC Figure 1
The effect of MP on IL-17 and IFN-γ gene expression 
and production in LNC. LNC isolated from DA rats (A, 
C-H) or AO rats (B) were stimulated with ConA (2.5 μg/ml) 
for 48 hours (A, B, E, F, H) or for various time periods (C, D) 
in the presence or absence of various MP concentrations (A, 
B), or with 10 ng/ml of MP (C-H). Subsequently, culture 
supernatants were collected for ELISA (A, B, C, D) or cells 
were collected for CFSE FACS analysis (H) or RNA isolation 
(E, F, G). Alternatively, cells were grown for additional 16 
hours in the presence of 3H-thymidine for proliferation assay 
(A). Results are presented as % of values obtained in corre-
sponding cultures without MP – control (A, B) or as concen-
trations (C, D), or as 2-dCt (E, F, G). CFSE staining profiles 
are: dark grey shadow – ConA, light grey line – ConA+MP, 
while the numbers in the table represent % of cells in corre-
sponding phase. *p < 0.05 represents statistically significant 
difference to the corresponding culture without MP.BMC Immunology 2008, 9:47 http://www.biomedcentral.com/1471-2172/9/47
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MP affected IL-17 production in LNC through direct influ-
ence on T cells and indirect influence on accessory cells.
Similarly to results obtained in LNC the effect of MP on
IL-17 production by purified T lymphocytes was weaker
than its influence on IFN-γ (Fig 3C, D). Interestingly, the
extent of MP induced IFN-γ inhibition was similar in LNC
and purified T cells, contrary to the difference observed in
the effect of MP on IL-17 production by LNC and purified
T cells (Fig 3A–D). In order to explore indirect influence
of MP on IL-17 production, which could be important for
the observed difference in efficiency of MP in inhibition
of IL-17 in purified T cells and LNC, CD3- cells were stim-
ulated with LPS in the presence or absence of MP and pro-
duction of a major IL-17-promoting cytokine – IL-6 was
determined. As a result it was shown that MP potently
inhibited IL-6 production in LPS-stimulated CD3- cells,
thus suggesting that indirect influence of MP on IL-17 pro-
duction could be, at least partly, conducted through inhi-
bition of IL-6 production by non-T cells.
Methylprednisolone cooperates with IFN-γ in reduction of 
IL-17 generation in lymph node cells
Having in mind that IFN-γ is inhibitory factor for IL-17
production (3, 4), and that we observed almost complete
reduction of IFN-γ, but not so extensive down-regulation
The effect of MP on MBP-specific production of IL-17 and  IFN-γ Figure 2
The effect of MP on MBP-specific production of IL-17 
and IFN-γ. DLNC isolated from 4 rats 6 days after immuni-
zation with SCH-CFA, or SCC isolated from 3 rats 10 days 
after immunization with SCH-CFA (clinical score – 1.5) were 
stimulated with MBP (10 μg/ml) and cultivated in the pres-
ence or absence of MP (10 ng/ml) for 72 hours. *p < 0.05 
represents statistically significant difference to the corre-
sponding culture without MP.
The effect of MP on IL-17 and IFN-γ production in T lym- phocytes Figure 3
The effect of MP on IL-17 and IFN-γ production in T 
lymphocytes. CD3+ cells and LNC were stimulated with 
anti-CD3 antibody and anti-CD28 antibody (both at 1 μg/ml) 
in the absence or presence of MP (10 ng/ml) for 24 (A, C) 
and 48 (B, D) hours, and cell culture supernatants analyzed 
for IL-17 (A, B) and IFN-γ (C, D). CD3- cells were stimulated 
with LPS (1 μg/ml) for 48 hours and cell culture supernatants 
analyzed for IL-6 (E). Results are presented as % of values 
obtained in the corresponding cultures without MP. *p < 
0.05 represents statistically significant difference to the cor-
responding culture without MP.BMC Immunology 2008, 9:47 http://www.biomedcentral.com/1471-2172/9/47
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of IL-17 by MP, our next step was to investigate if MP
spared IL-17 generation through eliminating the other
negative factor – IFN-γ. To that extent, LNC cultures stim-
ulated with ConA and treated with MP were simultane-
ously stimulated with recombinant IFN-γ. However, there
was no significant change in IL-17 production in the pres-
ence or absence of IFN-γ, irrespectively on the presence of
MP (Fig 4A). In parallel IFN-γ production was also deter-
mined, and although it was obvious that MP had really
pronounced effect on its production, the drug still did not
abrogate it completely (Fig 4B). Therefore it was interest-
ing to see what would happen if such remaining IFN-γ-
production would be further abolished by the addition of
neutralizing antibody specific for IFN-γ. As a result, such
an antibody, but not the irrelevant isotype control anti-
body, up-regulated IL-17 production, both in the presence
or absence of MP, thus suggesting that IFN-γ, even in a
minute quantity that persisted after MP inhibition was a
negative regulator of IL-17 in our experimental system,
and that it cooperated with MP in reduction of IL-17 gen-
eration in LNC.
Methylprednisolone inhibits Jun activation in ConA-
stimulated lymph node cells
Glucocorticoids bound to their receptors interfere with
cytokines production acting directly on the gene expres-
sion or indirectly on the signal transduction. Therefore,
the influence of MP on ConA-induced mitogen activated
protein kinases (MAPK) signaling in LNC was investi-
gated. LNC were stimulated with ConA and incubated
with or without MP (10 ng/ml) and/or ERK-inhibitor
(UO126, 20 μM), or p38-inhibitor (SB202190, 20 μM),
or JNK-inhibitor (SP600125, 40 μM). Both MP and every
of the signaling inhibitors used inhibited IL-17 produc-
tion in ConA-stimulated LNC (Fig 5A). Moreover, if MP
was combined with any of the inhibitors the inhibition
was more pronounced, thus implicating that MP did not
inhibit either ERK, or p38, or JNK signaling. Additionally,
The effect of IFN-γ addition or neutralization on the inhibi- tion of IL-17 production by MP Figure 4
The effect of IFN-γ addition or neutralization on the 
inhibition of IL-17 production by MP. LNC were stimu-
lated with ConA (2.5 μg/ml) and incubated with or without 
MP (10 ng/ml) and/or IFN-γ (IFN – 100 ng/ml), and/or anti-
IFN-γ-neutralizing antibody (a-IFN – 1 μg/ml) or isotype con-
trol antibody (a-Iso – 1 μg/ml) for 24 hours. Subsequently, 
culture supernatants were collected for ELISA and IL-17 (A) 
and IFN-γ(B) production was determined. *p < 0.05 repre-
sents statistically significant difference to control cultures 
(medium).
The effect of MP on MAPK signaling in ConA-stimulated  LNC Figure 5
The effect of MP on MAPK signaling in ConA-stimu-
lated LNC. A) LNC were stimulated with ConA (2.5 μg/ml) 
and incubated with or without MP (10 ng/ml) and/or ERK-
inhibitor (UO126, 20 μM), or p38-inhibitor (SB202190, 20 
μM), or Jnk-inhibitor (SP600125, 40 μM) for 24 hours. B) 
LNC cultivated with or without MP (10 ng/ml) for two hours 
and stimulated with ConA (2.5 μg/ml) for additional 40 min-
utes, were fixed and subjected to cELISA specific for phos-
phorylated ERK, p38, Jnk, Jun and c-Fos. cELISA results are 
presented as % of corresponding cultures without MP (con-
trol). *p < 0.05 represents statistically significant difference 
to the corresponding culture without MP.BMC Immunology 2008, 9:47 http://www.biomedcentral.com/1471-2172/9/47
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LNC pretreated with MP for two hours and subsequently
stimulated with ConA for 40 minutes were analyzed for
intracellular levels of phosphorylated ERK, p38 and JNK.
As a result, MP did not inhibit activation of these crucial
elements in MAPK signaling (Fig 5B). However, levels of
phosphorylated Jun were markedly decreased in the pres-
ence of MP (Fig 5B), thus implying importance of tran-
scription factor AP-1 (consisted of p-Jun and Fos) for the
observed inhibitory effect of MP.
Discussion
The present work is the first to show the efficiency of MP
in inhibition of IL-17 expression in rat LNC. Interestingly,
the effect of MP was less pronounced on IL-17 than on
IFN-γ. The observed inhibition was, at least partly, con-
ducted through inhibition of RorγT expression and activa-
tion of transcription factor AP-1 subunit – Jun.
Despite the evidence that some of the proinflammatory
effects of IL-17 can be antagonized by GCs [19,20], just a
few facts have been known about the influence of GCs on
IL-17 production. In one report, methylprednisolone
appeared to be only partially effective in blocking PMA/
ionomycin-triggered IL-17 production in vitro by lym-
phocytes from healthy humans in comparison to extreme
inhibitory action of Cyclosporin A in the same setting
[20]. The influence of GCs on IL-17 expression in vivo was
demonstrated in bronchial biopsy specimens of moder-
ate-to-severe asthma patients by showing that the elevated
number of IL-17 producing cells decreased to levels found
in normal controls after oral treatment with GCs [21]. The
present work accordingly proves that MP potently inhibits
IL-17 expression and production in a strong, mitogen-
stimulated T cell response, as well as in more subtle, anti-
gen-specific response of T lymphocytes. However, the
influence of MP is less effective if the drug is applied to
purified T cells than to mixed population of LNC, thus
suggesting that action of MP on IL-17 generation in rat
LNC includes both direct influence on T cells and indirect
influence on other LNC populations contributing to T
cells IL-17 production. Indeed, the capability of GCs to
affect activity of accessory LNC cells, including dendritic
cells and macrophages, both at the level of membrane
bound co-stimulatory molecules and cytokine production
was previously described [12]. Production of numerous
cytokines that have been shown important for the stimu-
lation of IL-17 in T cells, such as IL-1, TNF-α, IL-6, IL-18
[22,23], could be affected in macrophages and dendritic
cells by the influence of GCs [12,24]. In line with these
data, we demonstrated that MP inhibited IL-6 production
in LNC population devoid of T lymphocytes. It is thus
expected that MP affects IL-17 production in LNC more
potently than in purified T cells. Furthermore, among cells
of LN there are other cell types, besides T cells, that could
be relevant source of IL-17 [3], and that could contribute
to the observed difference. However, the same phenome-
non was not observed with IFN-γ, as MP had almost equal
inhibitory effect on T cells as on LNC. Therefore, it seems
that the direct effect of MP on T cells is crucial for IFN-γ
inhibition, and although it was convincingly demon-
strated that GK inhibit the production of IL-12, necessary
for Th1 differentiation [12,24], it is tempting to speculate
that additional influence through modulation of expres-
sion of molecules in accessory cells have minor contribu-
tion, if any. Although there are previous reports about the
inhibitory effect of GCs on IFN-γ production in spleen
cells [25], as well as on purified CD4+ cells [16] in rats, this
is for the first time that a comparative approach, including
both starting population and purified T cells, in the inves-
tigation of the influence of GC on IFN-γ production is
used. The potency of the direct effect of MP on IFN-γ pro-
duction in T cells is supported by recent findings that GCs
directly interfere with Tbet, the essential transcription fac-
tor of IFN-γ-producing cells [26]. Importantly, our results
convincingly demonstrate that MP inhibits IFN-γ produc-
tion more potently than IL-17 production, irrespectively
of experimental setting used. Additionally, we also
present evidence that small production of IFN-γ remained
after MP action is still adequate to inhibit IL-17 produc-
tion since the addition of anti-IFN-γ-neutralizing anti-
body eliminated such an inhibitory effect. Therefore, it
seems that although MP inhibits IFN-γ, they still cooper-
ate to limit IL-17 generation. The lack of deepening IL-17
inhibition by the addition of exogenous IFN-γ is unex-
pected but it might be explained by saturating effect of
IFN-γ that remained upon MP treatment. It is on future
investigations to explore if this complex in vitro relation is
paralleled in vivo, and to find about its significance for the
therapeutic efficiency of MP.
IL-17-producing cells are now considered to be the major
culprits in various autoimmune disorders, including RA,
IBD, MS, and/or their animal models, that were previ-
ously considered to be caused by IFN-γ-secreting Th1 cells
[2,22,27]. Although neutralization or deletion of IFN-γ
and/or molecules involved in IFN-γ production and effec-
tor functions paradoxically enhanced the autoimmunity
in some experimental models [2,28], the role of this
cytokine in organ-specific autoimmune diseases and its
relationship to Th17 cells have not been fully understood,
yet. A pivotal pathogenic role for IL-17 in the autoim-
mune response has been substantiated by attenuation of
these and other disorders with IL-17 neutralization by
anti-IL-17 antibodies or in mice genetically deficient for
IL-17 or IL-17 receptor (IL-17R) [2,22,27]. First indica-
tions about importance of Th17 cells for the pathogenesis
of autoimmune diseases in humans were elevated number
of IL-17-producing cells and IL-17 in patients' circulation
or at the sites of the autoimmune response and reduction
of these parameters with immunomodulatory therapyBMC Immunology 2008, 9:47 http://www.biomedcentral.com/1471-2172/9/47
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[2,22,27]. Regarding MS, significant increase in IL-17
gene-expression and elevation of number of IL-17-pro-
ducing CD4+ and CD8+ T cells in active lesions in compar-
ison to silent lesions, or normal tissue were reported
[29,30]. More direct evidence for the role of IL-17 in MS
has recently been presented by Kebir et al., as they showed
that human blood-brain barrier (BBB) endothelial cells in
MS lesions express receptors for IL-17, and that IL-17 dis-
rupts BBB tight junctions both in vitro and in vivo [31].
Th17 lymphocytes were also shown to transmigrate effi-
ciently across BBB endothelial cells, highly express
granzyme B, kill human neurons and promote CNS
inflammation through CD4+  lymphocyte recruitment
[31]. Taken together, these recent data clearly suggest the
importance of Th17 for the pathogenesis of MS. Our
results suggest that a part of the efficiency of GCs in the
therapy of MS, and other autoimmune diseases such as RA
and IBD, is achieved through reduction of IL-17 genera-
tion. However, GCs are not absolutely efficient in the
treatment of autoimmune disorders, as up to 30% of
patients suffering from various autoimmune disorders do
not respond adequately to the GC therapy [32]. In our
experimental settings, IL-17 production is less sensitive
than IFN-γ production to the influence of MP. Having in
mind suggested importance of IL-17 and redundancy of
IFN-γ for autoimmunity, one could speculate that the
refractoriness to the therapy with GCs could be, at least
partly, explained by the insufficient reduction of IL-17
production and possibly number and/or frequency of IL-
17-producing cells. The idea is acceptable for MS, where it
is known that the disease develops in various subjects as a
consequence of different pathogenic mechanisms [33].
Again it is possible that Th17 response of some patients
could be prevalent and those patients would therefore
have weaker response to GC treatment. It has recently
been reported that with patients refractory to GC therapy,
there is a prevalence of special population of
CD4+CD25int cells among CD4+ cells, and that this special
sub-set is capable to proliferate in the presence of high
dexamethasone concentrations [34]. Lee and co-authors
propose a new paradigm for patients resistant to GC ther-
apy, according to which GCs positively select
CD4+CD25int cells, thus generating a population of GC-
resistant T cells that perpetuate ongoing inflammation.
Additionally, it has recently been reported that in humans
TGF-β potently restricts Th17 cells that produce IFN-γ, but
not those that do not generate IFN-γ [35]. Taking into
account these recent findings, it is tempting to speculate
that GCs could also differentially affect IFN-γ-producing
and non-producing Th17 cells, which could explain the
overall difference in the efficiency of the effect of MP on
IFN-γ and IL-17 in our system.
GCs are generally considered to exert their immunosup-
pressive effects through genomic effect, i.e. modulating
activity of transcription factors [12,26,36]. Additionally,
there has been an accumulating number of evidence sug-
gesting non-genomic effects of GCs, exerted in signaling
pathways up-stream of transcription factors [12,26,36]. In
various experimental settings it has been shown that GCs
are able to affect MAPK activation and function
[12,26,36]. In our investigation, MP did not affect ERK
and p38 activation in rat LNC, while it had only limited,
statistically non-significant effect on JNK activation.
Accordingly, inhibitors of all of the three MAPKs collabo-
rated with MP in its action against IL-17 generation, thus
suggesting that MP did not use any of the signaling routes
for its effect on IL-17 production. Of course, the observed
collaboration between MP and any of the inhibitors
applied could also be a consequence of incomplete inac-
tivation of the signaling pathways by these agents. How-
ever, we could not test such possibility as higher
concentrations of MP or the inhibitors applied in our
experiments affected cell viability. Still, for ERK and p38
the results of cELISA completely support results with
inhibitors. However, situation with JNK is not as clear,
especially as in the same setting MP potently inhibited Jun
activation. This comes as a surprise, as it is presumed that
Jun can be phosphorylated only by the action of JNK. Still,
it was already reported that under the influence of dexam-
ethasone the rate of decrease in JNK enzyme activity was
more prominent than reduction in protein content [37].
Thus, in our case statistically insignificant reduction of p-
JNK concentration in cells could result in significant
down-regulation of Jun phosphorylation. Alternatively,
there are also reports about JNK-independent activation
of Jun [38,39] which would be supportive to hypothesis
that in our case JNK-independent effect of MP on Jun acti-
vation took place.
Conclusion
Our results add IL-17 to the list of cytokines production of
which could be down-regulated by the influence of GCs.
Additionally, we provide an interesting phenomenon of
differential sensitivity of IL-17 and IFN-γ production to
the influence of MP. Our ongoing research is thus dedi-
cated to the influence of MP on IL-17 and IFN-γ genera-
tion in vivo, and includes subsequent investigation of the
possible connection between resistance to GC-therapy
and Th17 cells.
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